⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Data MS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men

Karien C.M. Gosens Sjoerd H. van der Burg Marij J.P. Welters Sanne Boekestijn Nikki M. Loof Wim Quint Carel J.M. van Noesel Allard C. van der Wal Olivier Richel Wilhelmus J.T.A. Krebber Cornelis J.M. Melief Henry J.C. de Vries Jan M. Prins

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary material 1: Rationale for intradermal administration of the vaccine, the use of pegylated interferon-alpha-2b (PegIntron) as adjuvant, immune assays.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gosens et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db643587523883 https://doi.org/10.1158/1078-0432.27033997.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Data MS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men2024
2Supplementary Data MS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men2024
3Supplementary Data MS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men2024
4Supplementary Data TS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men2024
5Supplementary Data TS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men2024